1-20 of 21
Daniel J. Hicklin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CCR 20th Anniversary Commentary: In Search of Cetuximab's First Indication—Combination Therapy with Irinotecan in Colorectal Cancer

Daniel J. Hicklin
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (7): 1505–1507.
https://doi.org/10.1158/1078-0432.CCR-14-2553
Published: 31 March 2015
View article titled, <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: In Search of Cetuximab's First Indication—Combination Therapy with Irinotecan in Colorectal Cancer
Open the PDF for <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: In Search of Cetuximab's First Indication—Combination Therapy with Irinotecan in Colorectal Cancer in another window
Journal Articles

Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology

Lee M. Ellis, Daniel J. Hicklin
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (24): 7471–7478.
https://doi.org/10.1158/1078-0432.CCR-09-1070
Published: 14 December 2009
View article titled, Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
Open the PDF for Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology in another window
Journal Articles

Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy

Lee M. Ellis, Daniel J. Hicklin
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6371–6375.
https://doi.org/10.1158/1078-0432.CCR-07-5287
Published: 16 October 2008
View article titled, Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy
Open the PDF for Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy in another window
Journal Articles

Tumors Established with Cell Lines Selected for Oxaliplatin Resistance Respond to Oxaliplatin if Combined with Cetuximab

Marie Prewett, Dhanvanthri S. Deevi, Rajiv Bassi, Fan Fan, Lee M. Ellis, Daniel J. Hicklin, James R. Tonra
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (24): 7432–7440.
https://doi.org/10.1158/1078-0432.CCR-07-1768
Published: 19 December 2007
View article titled, Tumors Established with Cell Lines Selected for Oxaliplatin Resistance Respond to Oxaliplatin if Combined with Cetuximab
Open the PDF for Tumors Established with Cell Lines Selected for Oxaliplatin Resistance Respond to Oxaliplatin if Combined with Cetuximab in another window
Journal Articles

Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy

Hagop Youssoufian, Daniel J. Hicklin, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5544s–5548s.
https://doi.org/10.1158/1078-0432.CCR-07-1107
Published: 17 September 2007
View article titled, Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy
Open the PDF for Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy in another window
Journal Articles

Suppression of Ewing's Sarcoma Tumor Growth, Tumor Vessel Formation, and Vasculogenesis Following Anti–Vascular Endothelial Growth Factor Receptor-2 Therapy

Zhichao Zhou, Marcela F. Bolontrade, Krishna Reddy, Xiaoping Duan, Hui Guan, Ling Yu, Daniel J. Hicklin, Eugenie S. Kleinerman
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (16): 4867–4873.
https://doi.org/10.1158/1078-0432.CCR-07-0133
Published: 15 August 2007
View article titled, Suppression of Ewing's Sarcoma Tumor Growth, Tumor Vessel Formation, and Vasculogenesis Following Anti–Vascular Endothelial Growth Factor Receptor-2 Therapy
Open the PDF for Suppression of Ewing's Sarcoma Tumor Growth, Tumor Vessel Formation, and Vasculogenesis Following Anti–Vascular Endothelial Growth Factor Receptor-2 Therapy in another window
Journal Articles

A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism

Elizabeth A. Manning, John G.M. Ullman, James M. Leatherman, Justin M. Asquith, Timothy R. Hansen, Todd D. Armstrong, Daniel J. Hicklin, Elizabeth M. Jaffee, Leisha A. Emens
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (13): 3951–3959.
https://doi.org/10.1158/1078-0432.CCR-07-0374
Published: 02 July 2007
View article titled, A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism
Open the PDF for A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism in another window
Journal Articles

Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor

Philipp Steiner, Christopher Joynes, Rajiv Bassi, Su Wang, James R. Tonra, Yaron R. Hadari, Daniel J. Hicklin
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (5): 1540–1551.
https://doi.org/10.1158/1078-0432.CCR-06-1887
Published: 01 March 2007
View article titled, Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor
Open the PDF for Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor in another window
Journal Articles

Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer

Yan Wu, Zhaojing Zhong, James Huber, Rajiv Bassi, Bridget Finnerty, Erik Corcoran, Huiling Li, Elizabeth Navarro, Paul Balderes, Xenia Jimenez, Henry Koo, Venkata R.M. Mangalampalli, Dale L. Ludwig, James R. Tonra, Daniel J. Hicklin
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (21): 6573–6584.
https://doi.org/10.1158/1078-0432.CCR-06-0831
Published: 03 November 2006
View article titled, Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer
Open the PDF for Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer in another window
Journal Articles

Roles of Nitric Oxide Synthase Inhibition and Vascular Endothelial Growth Factor Receptor-2 Inhibition on Vascular Morphology and Function in an In vivo Model of Pancreatic Cancer

E. Ramsay Camp, Anthony Yang, Wenbiao Liu, Fan Fan, Ray Somcio, Daniel J. Hicklin, Lee M. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (8): 2628–2633.
https://doi.org/10.1158/1078-0432.CCR-05-2257
Published: 25 April 2006
View article titled, Roles of Nitric Oxide Synthase Inhibition and Vascular Endothelial Growth Factor Receptor-2 Inhibition on Vascular Morphology and Function in an <em>In vivo</em> Model of Pancreatic Cancer
Open the PDF for Roles of Nitric Oxide Synthase Inhibition and Vascular Endothelial Growth Factor Receptor-2 Inhibition on Vascular Morphology and Function in an <em>In vivo</em> Model of Pancreatic Cancer in another window
Journal Articles

Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy

James R. Tonra, Dhanvanthri S. Deevi, Erik Corcoran, Huiling Li, Su Wang, Francine E. Carrick, Daniel J. Hicklin
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (7): 2197–2207.
https://doi.org/10.1158/1078-0432.CCR-05-1682
Published: 11 April 2006
View article titled, Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy
Open the PDF for Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy in another window
Includes: Supplementary data
Journal Articles

Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts

Jeanne M. du Manoir, Giulio Francia, Shan Man, Miriam Mossoba, Jeffrey A. Medin, Alicia Viloria-Petit, Daniel J. Hicklin, Urban Emmenegger, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (3): 904–916.
https://doi.org/10.1158/1078-0432.CCR-05-1109
Published: 07 February 2006
View article titled, Strategies for Delaying or Treating <em>In vivo</em> Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts
Open the PDF for Strategies for Delaying or Treating <em>In vivo</em> Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts in another window
Journal Articles

Anti-Vascular Endothelial Growth Factor Receptor-2 Antibody Accelerates Renal Disease in the NZB/W F1 Murine Systemic Lupus Erythematosus Model

Hideaki Watanabe, Adam J. Mamelak, Elliot Weiss, Binghe Wang, Irwin Freed, Angela K. Brice, Lynn Wachtman, Kathleen L. Gabrielson, Naoko Yokota, Daniel J. Hicklin, Robert S. Kerbel, Mark Haas, Daniel N. Sauder
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (1): 407–409.
https://doi.org/10.1158/1078-0432.407.11.1
Published: 21 January 2005
View article titled, Anti-Vascular Endothelial Growth Factor Receptor-2 Antibody Accelerates Renal Disease in the NZB/W F<sub>1</sub> Murine Systemic Lupus Erythematosus Model
Open the PDF for Anti-Vascular Endothelial Growth Factor Receptor-2 Antibody Accelerates Renal Disease in the NZB/W F<sub>1</sub> Murine Systemic Lupus Erythematosus Model in another window
Journal Articles

Anti-Vascular Endothelial Growth Factor Receptor 2 Antibody Reduces Tumorigenicity and Metastasis in Orthotopic Prostate Cancer Xenografts via Induction of Endothelial Cell Apoptosis and Reduction of Endothelial Cell Matrix Metalloproteinase Type 9 Production

Paul Sweeney, Takashi Karashima, Sun-Jin Kim, Daniel Kedar, Badar Mian, Samuel Huang, Cheryl Baker, Zhen Fan, Daniel J. Hicklin, Curtis A. Pettaway, Colin P. N. Dinney
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (8): 2714–2724.
Published: 01 August 2002
View article titled, Anti-Vascular Endothelial Growth Factor Receptor 2 Antibody Reduces Tumorigenicity and Metastasis in Orthotopic Prostate Cancer Xenografts via Induction of Endothelial Cell Apoptosis and Reduction of Endothelial Cell Matrix Metalloproteinase Type 9 Production
Open the PDF for Anti-Vascular Endothelial Growth Factor Receptor 2 Antibody Reduces Tumorigenicity and Metastasis in Orthotopic Prostate Cancer Xenografts via Induction of Endothelial Cell Apoptosis and Reduction of Endothelial Cell Matrix Metalloproteinase Type 9 Production in another window
Journal Articles

Enhanced Antitumor Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody IMC-C225 in Combination with Irinotecan (CPT-11) against Human Colorectal Tumor Xenografts

Marie C. Prewett, Andrea T. Hooper, Rajiv Bassi, Lee M. Ellis, Harlan W. Waksal, Daniel J. Hicklin
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (5): 994–1003.
Published: 01 May 2002
View article titled, Enhanced Antitumor Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody IMC-C225 in Combination with Irinotecan (CPT-11) against Human Colorectal Tumor Xenografts
Open the PDF for Enhanced Antitumor Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody IMC-C225 in Combination with Irinotecan (CPT-11) against Human Colorectal Tumor Xenografts in another window
Journal Articles

Inhibition of Angiogenesis by the Antiepidermal Growth Factor Receptor Antibody ImClone C225 in Androgen-independent Prostate Cancer Growing Orthotopically in Nude Mice

Takashi Karashima, Paul Sweeney, Joel W. Slaton, Sun J. Kim, Daniel Kedar, Jonathan I. Izawa, Zhen Fan, Curtis Pettaway, Daniel J. Hicklin, Taro Shuin, Colin P. N. Dinney
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (5): 1253–1264.
Published: 01 May 2002
View article titled, Inhibition of Angiogenesis by the Antiepidermal Growth Factor Receptor Antibody ImClone C225 in Androgen-independent Prostate Cancer Growing Orthotopically in Nude Mice
Open the PDF for Inhibition of Angiogenesis by the Antiepidermal Growth Factor Receptor Antibody ImClone C225 in Androgen-independent Prostate Cancer Growing Orthotopically in Nude Mice in another window
Journal Articles

Paclitaxel Enhances the Effects of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody ImClone C225 in Mice with Metastatic Human Bladder Transitional Cell Carcinoma

Keiji Inoue, Joel W. Slaton, Paul Perrotte, Darren W. Davis, Christiane J. Bruns, Daniel J. Hicklin, David J. McConkey, Paul Sweeney, Robert Radinsky, Colin P. N. Dinney
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (12): 4874–4884.
Published: 01 December 2000
View article titled, Paclitaxel Enhances the Effects of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody ImClone C225 in Mice with Metastatic Human Bladder Transitional Cell Carcinoma
Open the PDF for Paclitaxel Enhances the Effects of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody ImClone C225 in Mice with Metastatic Human Bladder Transitional Cell Carcinoma in another window
Journal Articles

Treatment of Human Metastatic Transitional Cell Carcinoma of the Bladder in a Murine Model with the Anti-Vascular Endothelial Growth Factor Receptor Monoclonal Antibody DC101 and Paclitaxel

Keiji Inoue, Joel W. Slaton, Darren W. Davis, Daniel J. Hicklin, David J. McConkey, Takashi Karashima, Robert Radinsky, Colin P. N. Dinney
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (7): 2635–2643.
Published: 01 July 2000
View article titled, Treatment of Human Metastatic Transitional Cell Carcinoma of the Bladder in a Murine Model with the Anti-Vascular Endothelial Growth Factor Receptor Monoclonal Antibody DC101 and Paclitaxel
Open the PDF for Treatment of Human Metastatic Transitional Cell Carcinoma of the Bladder in a Murine Model with the Anti-Vascular Endothelial Growth Factor Receptor Monoclonal Antibody DC101 and Paclitaxel in another window
Journal Articles

Epidermal Growth Factor Receptor Blockade with C225 Plus Gemcitabine Results in Regression of Human Pancreatic Carcinoma Growing Orthotopically in Nude Mice by Antiangiogenic Mechanisms

Christiane J. Bruns, Matthew T. Harbison, Darren W. Davis, Charles A. Portera, Rachel Tsan, David J. McConkey, Douglas B. Evans, James L. Abbruzzese, Daniel J. Hicklin, Robert Radinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (5): 1936–1948.
Published: 01 May 2000
View article titled, Epidermal Growth Factor Receptor Blockade with C225 Plus Gemcitabine Results in Regression of Human Pancreatic Carcinoma Growing Orthotopically in Nude Mice by Antiangiogenic Mechanisms
Open the PDF for Epidermal Growth Factor Receptor Blockade with C225 Plus Gemcitabine Results in Regression of Human Pancreatic Carcinoma Growing Orthotopically in Nude Mice by Antiangiogenic Mechanisms in another window
Journal Articles

Vascular Endothelial Growth Factor Levels and Induction of Permeability in Malignant Pleural Effusions

Brian K. Zebrowski, Seiji Yano, Wenbiao Liu, Raymond M. Shaheen, Daniel J. Hicklin, Joe B. Putnam, Jr., Lee M. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (11): 3364–3368.
Published: 01 November 1999
View article titled, Vascular Endothelial Growth Factor Levels and Induction of Permeability in Malignant Pleural Effusions
Open the PDF for Vascular Endothelial Growth Factor Levels and Induction of Permeability in Malignant Pleural Effusions in another window